The recommended dose for LORVIQUA® is 100mg taken orally, once daily. Treatment with LORVIQUA® should be continued until disease progression or unacceptable toxicity.¹

Please note: a reduced dose of LORVIQUA® is recommended in patients with severe renal impairment (absolute eGFR < 30 mL/min), e.g. a once daily starting dose of 75 mg taken orally.¹ 

Tablets should be swallowed whole at approximately the same time every day, with or without food. Patients should take a missed dose as soon as it is remembered unless it is less than four hours before their next dose is due, in which case the missed dose should not be taken. Patients should not take two doses at the same time to make up for missed doses.¹

Dosing interruption or dose reduction may be required, based on individual tolerability.¹ 

LORVIQUA® dose reduction levels are¹:

- First dose reduction: 75mg taken orally once daily
- Second dose reduction: 50mg taken orally once daily

LORVIQUA® should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily.¹

Treatment with LORVIQUA® is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity.¹​​​​​​​

For the most up-to-date safety information and full information on dose modifications and the management of treatment related adverse events, please refer to the LORVIQUA® Summary of Product Characteristics.

eGFR: Estimated Glomerular Filtration Rate
 

LORVIQUA®▼(lorlatinib) Prescribing Information for Great Britain and Northern Ireland click here.
XALKORI® (crizotinib) Prescribing Information for Great Britain and Northern Ireland click here.